Skip to content
value.today

Indaptus Therapeutics, Inc.

🇺🇸 New York, New York, USAPharmaceuticalsFounded 2021

Formerly INTEC PARENT, INC.

Indaptus Therapeutics, Inc. is listed today as Indaptus Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Indaptus Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$2 MPrivate placement after listing$2 to $10 million

Indaptus Therapeutics, Inc.: Private sale, Jun 2025

Investors in this round

20 investors had bought by the notice of Jun 20, 2025: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Indaptus Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$600,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey A. Meckler · Executive Officer, Director
  • Michael J Newman · Executive Officer, Director
  • Nir J Sassi · Executive Officer
  • Roger J. Waltzman · Executive Officer
  • Walt A. Linscott · Executive Officer
  • Anthony J. Maddaluna · Director
  • Hila J. Karah · Director
  • Mark J. Gilbert · Director
  • Robert E. Martell · Director
  • Roger J. Pomerantz · Director
  • William B. Hayes · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 000005670) · Portland, OregonSold in CA, CO, FL, GA, HI, ID, IL, KS, MA, MD, MI, MN, NC, NJ, NV, NY, OK, OR, PA, SC, TX, UT, VA, WA, WI, and outside the US

Remarks in the notice

  • On fees: “The Issuer paid the placement agent (i) 12% of gross proceeds in the offering, (ii) a $25,000 non-accountable expense and (iii) a number of warrants equal to 12% of the shares issuable upon conversion of the notes sold in the offering.”
  • On the amounts: “Offering of convertible notes in the aggregate principal amount of up to $5 million, convertible into shares of common stock, together with warrants to purchase shares of common stock. Approximately $2.3 million raised as of initial closing date.”
  • On the use of proceeds: “The Company intends to use the net proceeds from the Offering for research and development activities including the funding of a Phase 1b/2 clinical trial as well as for working capital and general corporate purposes.”

Signed by Nir Sassi, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 20, 2025. Read the notice at the SEC.

optionsSEC
Jan 2025$2 MPrivate placement after listing$2 to $10 million

Indaptus Therapeutics, Inc.: Private sale, Jan 2025

Investors in this round

16 investors had bought by the notice of Jan 22, 2025: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Indaptus Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: 2,109,383 shares of Common Stock and common warrants to purchase up to 2,109,383 shares of Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$157,255
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey A. Meckler · Executive Officer, Director
  • Michael J. Newman · Executive Officer, Director
  • Nir A Sassi · Executive Officer
  • Roger J. Waltzman · Executive Officer
  • Walt A Linscott · Executive Officer
  • Anthony J. Maddaluna · Director
  • Hila J. Karah · Director
  • Mark J Gilbert · Director
  • Robert E. Martell · Director
  • Roger J. Pomerantz · Director
  • William B. Hayes · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paulson Investment Company, LLC (CRD 000005670) · Portland, OregonSold in all US states

Remarks in the notice

  • On fees: “The Issuer paid placement agent 7% of gross proceeds & issued placement agent warrants to purchase up to 147,656 shares (exercise price per share equal to $1.175) & paid a non-accountable sum of $25,000.”
  • On the amounts: “Offering of 2,109,383 unregistered shares of Common Stock and unregistered warrants to purchase up to 2,109,383 shares of Common Stock.”

Signed by Nir Sassi, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 22, 2025. Read the notice at the SEC.

equity, optionsSEC
Jul 2021$30 MIssued in a merger or acquisition$10 to $50 million

Indaptus Therapeutics, Inc.: Private sale, Jul 2021

Investors in this round

1 investor had bought by the notice of Aug 5, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Indaptus Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,100,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey A. Meckler · Executive Officer, Director
  • Michael A Newman · Executive Officer, Director
  • Nir A Sassi · Executive Officer
  • Walt A Linscott · Executive Officer
  • Anthony J. Maddaluna · Director
  • Brian J. O'Callaghan · Director
  • Hila W. Karah · Director
  • Hoonmo A Lee · Director
  • Roger J. Pomerantz · Director
  • William B. Hayes · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “$420,000 of the $2,100,000 is paid to Ladenburg Thalmann and Maxim Group, as financial advisors. Wainwright also entitled to: management fee of 1.75% of the proceeds, $25,000non-accountable expense, $50,000legal fees, 136,364 warrants at $13.75 per share.”
  • On the amounts: “Offering and issuance of an unregistered pre-funded warrant to purchase up to 2,727,273 shares of Common Stock and an accompanying unregistered warrant to purchase up to 2,727,273 shares of Common Stock.”
  • On the use of proceeds: “Issuer expects to use proceeds from the offering for working capital purposes, which includes payment of salaries to the named executive officers.”
  • On a merger: “The Private Placement is consummated to satisfy a closing condition of the merger agreement between the Company, Intec Israel, Domestication Merger Sub Ltd,, Dillon Merger Subsidiary, Inc. and Decoy Biosystems, Inc., which was announced on March 15, 2021.”

Signed by Nir Sassi, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 5, 2021. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Indaptus Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2025).

    SEC Form D · Jun 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2025

That is all the official record says: Indaptus Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Indaptus Therapeutics, Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Indaptus Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
David E. LazarPersonnot statednot statedHeld Series AA and AAA preferred stock (Form 3, 2025)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Indaptus Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Indaptus Therapeutics, Inc.
NameRoleNamed in
Jeffrey A. MecklerExecutive officerJun 2025
Michael J NewmanExecutive officerJun 2025
Nir J SassiExecutive officerJun 2025
Roger J. WaltzmanExecutive officerJun 2025
Walt A. LinscottExecutive officerJun 2025
Michael J. NewmanExecutive officerJan 2025
Nir A SassiExecutive officerJan 2025
Walt A LinscottExecutive officerJan 2025
Michael A NewmanExecutive officerAug 2021
Anthony J. MaddalunaDirectorJun 2025
Hila J. KarahDirectorJun 2025
Jeffrey A. MecklerDirectorJun 2025
Mark J. GilbertDirectorJun 2025
Michael J NewmanDirectorJun 2025
Robert E. MartellDirectorJun 2025
Roger J. PomerantzDirectorJun 2025
William B. HayesDirectorJun 2025
Mark J GilbertDirectorJan 2025
Michael J. NewmanDirectorJan 2025
Brian J. O'CallaghanDirectorAug 2021
Hila W. KarahDirectorAug 2021
Hoonmo A LeeDirectorAug 2021
Michael A NewmanDirectorAug 2021

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.